XLV241220P205000
- 0.00
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Eli Lilly Stock Is Rising Monday: What's Going On?
Anavex Stock Rallies 30% on Business Updates
Weekly ETF Flows: Seven Out of 11 Sectors Record Outflows; Bitcoin Continues to Lead With Higher Inflows
14 Analysts Have This To Say About Danaher
Unpacking the Latest Options Trading Trends in UnitedHealth Group
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
ResMed, Inspire Medical Fall After Lilly's Zepbound Gains Sleep Apnea Indication
2024's 'Biggest Loses' That Could See Reversal in 2025
Danaher Analyst Ratings
Thermo Fisher Scientific Analyst Ratings
Sector Update: Health Care Stocks Fall Premarket Monday
ETF Shorts Were up Last Week, Led by Large-cap ETFs
Leading And Lagging Sectors For December 23, 2024
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday as Investors Assess Fed's Interest Rate Outlook
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.
① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.